重组人促红细胞生成素在多发性骨髓瘤中的应用进展_West China Medical Journal

Authors：

曾艳 ,  徐才刚

Corresponding author：

徐才刚, Email: syzengyan@163.com

Keywords：

多发性骨髓瘤; 重组人促红细胞生成素; 内源性促红细胞生成素; 应用; 进展

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

多发性骨髓瘤（MM）是一种源于浆细胞的恶性肿瘤，其典型临床表现有贫血、骨痛、肾功能损害和感染，而贫血是其最常见表现。临床上仍以药物化学治疗和骨髓移植作为其治疗方案。随着对重组人促红细胞生成素（rHuEpo）作用机制及MM的发病机制深入研究，rHuEpo在MM治疗中的临床应用日益广泛。近年的研究表明，rHuEpo既能改善MM相关性贫血、还有一定抗骨髓瘤效应，抗骨髓瘤机制还有待进一步研究。

Citation： 曾艳,徐才刚. 重组人促红细胞生成素在多发性骨髓瘤中的应用进展. West China Medical Journal, 2012, 27(5): 786-788. doi: Copy

1.	Robert A, Kyleand S, Rajkumar V. Multiple myeloma[J]. Blood, 2008, 111(6): 2962-2972.
2.	Ludwing H, Fritz E, Kotzmann H, et al. Erythropoietin treatment of anemia associated with mutiple myeloma[J]. N Engl J Med, 1990, 322(24): 1693-1699.
3.	雷建蓉.人类重组红细胞生成素作用的研究进展[J].重庆医学, 2000, 29(5): 469-470.
4.	Farrell F, Lee A. The erythropoietm receptor and its expression in tumor cells and other tissues[J]. Oncologist, 2004, 9: 18-30.
5.	邓刚. 促红细胞生成素及其受体与细胞凋亡[J]. 国际儿科学杂志, 2009, 36(3): 309-312.
6.	Beguin Y, Yerna M, Loo M, et al. Erythropoietin in mutiple myeloma:defective red cell production due to inappropriate erythropoietin production[J]. Br J Haematol, 1992, 82(4): 648-653.
7.	Dammacco F, Castoldi G, Rodier S. Efficacy of epoetin alpha in the treatment of anemia of multiple myeloma[J]. Br J Haematol, 2001, 113(1): 172-179.
8.	赵莹, 李娟, 罗绍凯, 等. 大剂量促红细胞生成素冲击在治疗多发性骨髓瘤贫血中的应用[J]. 国际输血及血液学杂志, 2007, 30(4): 305-308.
9.	刘瑜, 徐娟, 常红, 等. 大剂量重组人促红细胞生成素在多发性骨髓瘤贫血中的应用[J]. 华西医学, 2009, 24(5): 1147-1150.
10.	王凤丹, 周道斌, 李淑兰, 等. 重组人红细胞生成素对人多发性骨髓瘤患者铁调节蛋白Hepcidin mRNA表达的影响[J]. 中国实验血液血杂志2011, 19(2): 390-394.
11.	Shen Y, Ma J, Zhu HL,et al. A multi-center open-labeled study of recombinant erythropoietin-β in the treatment of anemic patients with multiple myeloma, low-grade non-Hodgkin’s lymphoma, or chronic lymphocytic leukemia in Chinese population[J]. Int J Hematol, 2008, 88(2): 139-144.
12.	Mittelman M, Zeidman A, Kanter P, et al. Erythropoietin has an anti-myeloma effect: a hypothesis based on a clinical observation supported by animal studies[J]. Eur J Haematol, 2004, 72: 155-165.
13.	Katz O, Barzilay E, Skaat A, et al. Erythropoietin induced tumour mass reduction in murine lymphoproliferative models[J]. Acaematol. 2005, 114(3): 177-179.
14.	Mittelman M, Neumann D, Peled A, et al. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models[J]. Proc Natl Acad Sci USA, 2001, 98(9): 5181-5186.
15.	Baz R, Brand C, McGowan B, et al. High dose recombinant human erythropoietin use is associated with increased overall survival in patients with multiple myeloma[J]. Clin Oncol, 2005, 232(16): 6621-6621.
16.	Prutchi-Sagiv S, Golishevsky N, Oster HS, et al. Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease[J]. Br J Haematol, 2006, 135(5): 660-672.
17.	Katz O, Gil L, Lifshitz L, et al. Erythropoietin enhances immune responses in mice[J]. Eur J Immunol, 2007, 37(6): 1584-1593.
18.	Lifshhitz L, Tabak G, Gassmann M, et al. Macrophages as novel target cells for erythropoietin[J]. Haematolodical, 2010, 95(11): 1823-1831.
19.	Lifshitz L, Prutchi-Sagiv S, Avneon M, et al. Non-erythroid activites of Erythropoietin: functional effects on murine dendritic cells[J]. Mol Immunol, 2009, 46(4): 713-721.
20.	Nguyena AN, Stebbinsa EG, Hensona M, et al. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation[J]. Exp Cell Res, 2006, 312(10): 1909-1923.
21.	郭益群, 陈世伦. 多发性骨髓瘤骨髓基质细胞分泌IGF-1、VEGF和IL-6的动态变化[J]. 中华血液学杂志, 2006, 27(4): 231-234.
22.	周美玉, 刘瑜, 孟文彤, 等. 重组人促红细胞生成素治疗多发性骨髓瘤小鼠的疗效与机制的研究[J]. 四川大学学报(医学版), 2010, 41(5): 797-802.

1. 　Robert A, Kyleand S, Rajkumar V. Multiple myeloma[J]. Blood, 2008, 111(6): 2962-2972.
2. 　Ludwing H, Fritz E, Kotzmann H, et al. Erythropoietin treatment of anemia associated with mutiple myeloma[J]. N Engl J Med, 1990, 322(24): 1693-1699.
3. 　雷建蓉.人类重组红细胞生成素作用的研究进展[J].重庆医学, 2000, 29(5): 469-470.
4. 　Farrell F, Lee A. The erythropoietm receptor and its expression in tumor cells and other tissues[J]. Oncologist, 2004, 9: 18-30.
5. 　邓刚. 促红细胞生成素及其受体与细胞凋亡[J]. 国际儿科学杂志, 2009, 36(3): 309-312.
6. 　Beguin Y, Yerna M, Loo M, et al. Erythropoietin in mutiple myeloma:defective red cell production due to inappropriate erythropoietin production[J]. Br J Haematol, 1992, 82(4): 648-653.
7. 　Dammacco F, Castoldi G, Rodier S. Efficacy of epoetin alpha in the treatment of anemia of multiple myeloma[J]. Br J Haematol, 2001, 113(1): 172-179.
8. 　赵莹, 李娟, 罗绍凯, 等. 大剂量促红细胞生成素冲击在治疗多发性骨髓瘤贫血中的应用[J]. 国际输血及血液学杂志, 2007, 30(4): 305-308.
9. 　刘瑜, 徐娟, 常红, 等. 大剂量重组人促红细胞生成素在多发性骨髓瘤贫血中的应用[J]. 华西医学, 2009, 24(5): 1147-1150.
10. 　王凤丹, 周道斌, 李淑兰, 等. 重组人红细胞生成素对人多发性骨髓瘤患者铁调节蛋白Hepcidin mRNA表达的影响[J]. 中国实验血液血杂志2011, 19(2): 390-394.
11. 　Shen Y, Ma J, Zhu HL,et al. A multi-center open-labeled study of recombinant erythropoietin-β in the treatment of anemic patients with multiple myeloma, low-grade non-Hodgkin’s lymphoma, or chronic lymphocytic leukemia in Chinese population[J]. Int J Hematol, 2008, 88(2): 139-144.
12. 　Mittelman M, Zeidman A, Kanter P, et al. Erythropoietin has an anti-myeloma effect: a hypothesis based on a clinical observation supported by animal studies[J]. Eur J Haematol, 2004, 72: 155-165.
13. 　Katz O, Barzilay E, Skaat A, et al. Erythropoietin induced tumour mass reduction in murine lymphoproliferative models[J]. Acaematol. 2005, 114(3): 177-179.
14. 　Mittelman M, Neumann D, Peled A, et al. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models[J]. Proc Natl Acad Sci USA, 2001, 98(9): 5181-5186.
15. 　Baz R, Brand C, McGowan B, et al. High dose recombinant human erythropoietin use is associated with increased overall survival in patients with multiple myeloma[J]. Clin Oncol, 2005, 232(16): 6621-6621.
16. 　Prutchi-Sagiv S, Golishevsky N, Oster HS, et al. Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease[J]. Br J Haematol, 2006, 135(5): 660-672.
17. 　Katz O, Gil L, Lifshitz L, et al. Erythropoietin enhances immune responses in mice[J]. Eur J Immunol, 2007, 37(6): 1584-1593.
18. 　Lifshhitz L, Tabak G, Gassmann M, et al. Macrophages as novel target cells for erythropoietin[J]. Haematolodical, 2010, 95(11): 1823-1831.
19. 　Lifshitz L, Prutchi-Sagiv S, Avneon M, et al. Non-erythroid activites of Erythropoietin: functional effects on murine dendritic cells[J]. Mol Immunol, 2009, 46(4): 713-721.
20. 　Nguyena AN, Stebbinsa EG, Hensona M, et al. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation[J]. Exp Cell Res, 2006, 312(10): 1909-1923.
21. 　郭益群, 陈世伦. 多发性骨髓瘤骨髓基质细胞分泌IGF-1、VEGF和IL-6的动态变化[J]. 中华血液学杂志, 2006, 27(4): 231-234.
22. 　周美玉, 刘瑜, 孟文彤, 等. 重组人促红细胞生成素治疗多发性骨髓瘤小鼠的疗效与机制的研究[J]. 四川大学学报(医学版), 2010, 41(5): 797-802.

West China Medical Journal

重组人促红细胞生成素在多发性骨髓瘤中的应用进展

Abstract Full text Figures/Tables Video References Cited by

Format

Content